RxDoctor Payments DataLook up a doctor →

Layla McDaniel, PA

Physician Assistant · Jacksonville, FLNPI 1497190524

Payments from drug & device makers

$74,373in general payments, 2019–2025

Across 723 payments — averaging $102.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$61K
  • AbbVie$3K
  • Amgen$2K
  • Johnson & Johnson$1K
  • AstraZeneca$1K
  • UCB, Inc.$1K
  • plus $5K from 24 others

What the payments were for

  • Food & beverage$13,44198%
  • Education$2552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,373 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$252,361
Medicare patients
593
Services billed
7,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab57$493,931
Simponi AriaGolimumab54$459,421
RinvoqUpadacitinib54$373,399
Xeljanz XrTofacitinib Citrate39$260,207
Enbrel MiniEtanercept23$244,072
Orencia ClickjectAbatacept36$229,082
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5069$222,491
Enbrel SureclickEtanercept27$218,652
Cimzia (2 Pack)Certolizumab Pegol21$176,027
KevzaraSarilumab24$105,643
RemicadeInfliximab15$103,886
ProliaDenosumab48$86,201
OtezlaApremilast15$70,163
ForteoTeriparatide11$58,761
Hydroxychloroquine Sulfate324$15,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSimponi Aria, Remicade$1,450$563,30769 claims
AbbVieRinvoq$2,501$373,39954 claims
UCB, Inc.Cimzia (2 Pack)$1,136$176,02721 claims
AmgenProlia, Otezla$2,277$156,36463 claims
SanofiKevzara$132$105,64324 claims
Lilly USA, LLCForteo$438$58,76111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →